SOLID TUMORS

PI3 kinase is well established as a central signaling pathway in cancer, playing a prominent role in cancer cell proliferation and survival.

Inhibiting specific isoforms of the PI3K may provide therapeutic effects without broadly inhibiting the PI3K signaling that is critical to the normal function of healthy cells.

PI3K Beta Isoform in Solid Tumor Malignancies

The biology of the PI3 kinase pathway in oncogenesis is evolving and the role of the beta isoform of PI3 kinase is of increased interest as potential anti-cancer target in tumors that lack a specific protein called PTEN.

Loss of PTEN function is the second most common mutation in solid tumors. It is associated with increased tumor cell proliferation and survival.

Calistoga Pharmaceuticals is evaluating PI3K beta inhibitors in preclinical studies.
Recommended Websites